Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy
Background Peroxynitrite, a product of the reaction of superoxide with nitric oxide, causes oxidative stress with concomitant inactivation of enzymes, poly(ADP‐ribosylation), mitochondrial dysfunction and impaired stress signalling, as well as protein nitration. In this study, we sought to determine...
Gespeichert in:
Veröffentlicht in: | Diabetes/metabolism research and reviews 2014-11, Vol.30 (8), p.669-678 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 678 |
---|---|
container_issue | 8 |
container_start_page | 669 |
container_title | Diabetes/metabolism research and reviews |
container_volume | 30 |
creator | Stavniichuk, Roman Shevalye, Hanna Lupachyk, Sergey Obrosov, Alexander Groves, John T. Obrosova, Irina G. Yorek, Mark A. |
description | Background
Peroxynitrite, a product of the reaction of superoxide with nitric oxide, causes oxidative stress with concomitant inactivation of enzymes, poly(ADP‐ribosylation), mitochondrial dysfunction and impaired stress signalling, as well as protein nitration. In this study, we sought to determine the effect of preventing protein nitration or increasing peroxynitrite decomposition on diabetic neuropathy in mice after an extended period of untreated diabetes.
Methods
C57Bl6/J male control and diabetic mice were treated with the peroxynitrite decomposition catalyst Fe(III) tetramesitylporphyrin octasulfonate (FeTMPS, 10 mg/kg/day) or protein nitration inhibitor (−)‐epicatechin gallate (20 mg/kg/day) for 4 weeks, after an initial 28 weeks of hyperglycaemia.
Results
Untreated diabetic mice developed motor and sensory nerve conduction velocity deficits, thermal and mechanical hypoalgesia, tactile allodynia and loss of intraepidermal nerve fibres. Both FeTMPS and epicatechin gallate partially corrected sensory nerve conduction slowing and small sensory nerve fibre dysfunction without alleviation of hyperglycaemia. Correction of motor nerve conduction deficit and increase in intraepidermal nerve fibre density were found with FeTMPS treatment only.
Conclusions
Peroxynitrite injury and protein nitration are implicated in the development of diabetic peripheral neuropathy. The findings indicate that both structural and functional changes of chronic diabetic peripheral neuropathy can be reversed and provide rationale for the development of a new generation of antioxidants and peroxynitrite decomposition catalysts for treatment of diabetic peripheral neuropathy. Published in 2014. This article is a U.S. Government work and is in the public domain in the USA. |
doi_str_mv | 10.1002/dmrr.2549 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4177961</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3495560001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5149-79573b83de54e0d2c167fc430c7c4640502f7b1bf0e076550226033c89062e503</originalsourceid><addsrcrecordid>eNp1kVtv1DAQhSMEohd44A-gSLyUh7Rjx5fNCxIsbUEqF-2CEE-W40y6Llk7tRPo_vs62mUFSDzZ4_nm6HhOlj0jcEoA6FmzDuGUclY9yA4Jp1BILuDh_s7pQXYU4w0AlEywx9kBZWImGZeH2ffPGPzdxtkh2AFz7Zq8D35A6_LpTQ_WuzwVwwrzXg8rf40Oo425b_PG6hoHa_Ieg-1XGHSXOxyDn8DNk-xRq7uIT3fncfb14vzL_F1x9eny_fz1VWE4YVUhKy7LelY2yBlCQw0RsjWsBCNNMgscaCtrUreAIAVPJRVQlmZWgaDIoTzOXm11-7FeY2PQJdud6oNd67BRXlv1d8fZlbr2PxUjUlaCJIGTnUDwtyPGQa1tNNh12qEfoyKiYpUUACyhL_5Bb_wYXPpeoigHSLvmiXq5pUzwMQZs92YIqCkwNQWmpsAS-_xP93vyd0IJONsCv2yHm_8rqbcfFoudZLGdsHHAu_2EDj-UkKXk6tvHS8WX4s1suZyrRXkPW2iwHQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1625005525</pqid></control><display><type>article</type><title>Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Stavniichuk, Roman ; Shevalye, Hanna ; Lupachyk, Sergey ; Obrosov, Alexander ; Groves, John T. ; Obrosova, Irina G. ; Yorek, Mark A.</creator><creatorcontrib>Stavniichuk, Roman ; Shevalye, Hanna ; Lupachyk, Sergey ; Obrosov, Alexander ; Groves, John T. ; Obrosova, Irina G. ; Yorek, Mark A.</creatorcontrib><description>Background
Peroxynitrite, a product of the reaction of superoxide with nitric oxide, causes oxidative stress with concomitant inactivation of enzymes, poly(ADP‐ribosylation), mitochondrial dysfunction and impaired stress signalling, as well as protein nitration. In this study, we sought to determine the effect of preventing protein nitration or increasing peroxynitrite decomposition on diabetic neuropathy in mice after an extended period of untreated diabetes.
Methods
C57Bl6/J male control and diabetic mice were treated with the peroxynitrite decomposition catalyst Fe(III) tetramesitylporphyrin octasulfonate (FeTMPS, 10 mg/kg/day) or protein nitration inhibitor (−)‐epicatechin gallate (20 mg/kg/day) for 4 weeks, after an initial 28 weeks of hyperglycaemia.
Results
Untreated diabetic mice developed motor and sensory nerve conduction velocity deficits, thermal and mechanical hypoalgesia, tactile allodynia and loss of intraepidermal nerve fibres. Both FeTMPS and epicatechin gallate partially corrected sensory nerve conduction slowing and small sensory nerve fibre dysfunction without alleviation of hyperglycaemia. Correction of motor nerve conduction deficit and increase in intraepidermal nerve fibre density were found with FeTMPS treatment only.
Conclusions
Peroxynitrite injury and protein nitration are implicated in the development of diabetic peripheral neuropathy. The findings indicate that both structural and functional changes of chronic diabetic peripheral neuropathy can be reversed and provide rationale for the development of a new generation of antioxidants and peroxynitrite decomposition catalysts for treatment of diabetic peripheral neuropathy. Published in 2014. This article is a U.S. Government work and is in the public domain in the USA.</description><identifier>ISSN: 1520-7552</identifier><identifier>EISSN: 1520-7560</identifier><identifier>DOI: 10.1002/dmrr.2549</identifier><identifier>PMID: 24687457</identifier><identifier>CODEN: DMRRFM</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Animals ; antioxidants ; Antioxidants - adverse effects ; Antioxidants - therapeutic use ; Behavior, Animal - drug effects ; Catechin - adverse effects ; Catechin - analogs & derivatives ; Catechin - therapeutic use ; Diabetes Mellitus, Type 1 - complications ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetic Neuropathies - metabolism ; Diabetic Neuropathies - pathology ; Diabetic Neuropathies - physiopathology ; Diabetic Neuropathies - prevention & control ; diabetic neuropathy ; Epidermis - drug effects ; Epidermis - innervation ; Epidermis - metabolism ; Epidermis - pathology ; Ferric Compounds - adverse effects ; Ferric Compounds - therapeutic use ; Ganglia, Spinal - drug effects ; Ganglia, Spinal - metabolism ; Ganglia, Spinal - pathology ; Male ; Metalloporphyrins - adverse effects ; Metalloporphyrins - therapeutic use ; Mice, Inbred C57BL ; Motor Neurons - drug effects ; Motor Neurons - metabolism ; Motor Neurons - pathology ; Nerve Tissue Proteins - metabolism ; Neural Conduction - drug effects ; nitrosative stress ; oxidative stress ; Oxidative Stress - drug effects ; Peripheral Nervous System - drug effects ; Peripheral Nervous System - metabolism ; Peripheral Nervous System - pathology ; Peripheral Nervous System - physiopathology ; peroxynitrite ; Peroxynitrous Acid - antagonists & inhibitors ; Peroxynitrous Acid - metabolism ; Reaction Time - drug effects ; Sensory Receptor Cells - drug effects ; Sensory Receptor Cells - metabolism ; Sensory Receptor Cells - pathology ; superoxide</subject><ispartof>Diabetes/metabolism research and reviews, 2014-11, Vol.30 (8), p.669-678</ispartof><rights>Published in 2014. This article is a U.S. Government work and is in the public domain in the USA.</rights><rights>Copyright © 2014 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5149-79573b83de54e0d2c167fc430c7c4640502f7b1bf0e076550226033c89062e503</citedby><cites>FETCH-LOGICAL-c5149-79573b83de54e0d2c167fc430c7c4640502f7b1bf0e076550226033c89062e503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fdmrr.2549$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fdmrr.2549$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24687457$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stavniichuk, Roman</creatorcontrib><creatorcontrib>Shevalye, Hanna</creatorcontrib><creatorcontrib>Lupachyk, Sergey</creatorcontrib><creatorcontrib>Obrosov, Alexander</creatorcontrib><creatorcontrib>Groves, John T.</creatorcontrib><creatorcontrib>Obrosova, Irina G.</creatorcontrib><creatorcontrib>Yorek, Mark A.</creatorcontrib><title>Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy</title><title>Diabetes/metabolism research and reviews</title><addtitle>Diabetes Metab Res Rev</addtitle><description>Background
Peroxynitrite, a product of the reaction of superoxide with nitric oxide, causes oxidative stress with concomitant inactivation of enzymes, poly(ADP‐ribosylation), mitochondrial dysfunction and impaired stress signalling, as well as protein nitration. In this study, we sought to determine the effect of preventing protein nitration or increasing peroxynitrite decomposition on diabetic neuropathy in mice after an extended period of untreated diabetes.
Methods
C57Bl6/J male control and diabetic mice were treated with the peroxynitrite decomposition catalyst Fe(III) tetramesitylporphyrin octasulfonate (FeTMPS, 10 mg/kg/day) or protein nitration inhibitor (−)‐epicatechin gallate (20 mg/kg/day) for 4 weeks, after an initial 28 weeks of hyperglycaemia.
Results
Untreated diabetic mice developed motor and sensory nerve conduction velocity deficits, thermal and mechanical hypoalgesia, tactile allodynia and loss of intraepidermal nerve fibres. Both FeTMPS and epicatechin gallate partially corrected sensory nerve conduction slowing and small sensory nerve fibre dysfunction without alleviation of hyperglycaemia. Correction of motor nerve conduction deficit and increase in intraepidermal nerve fibre density were found with FeTMPS treatment only.
Conclusions
Peroxynitrite injury and protein nitration are implicated in the development of diabetic peripheral neuropathy. The findings indicate that both structural and functional changes of chronic diabetic peripheral neuropathy can be reversed and provide rationale for the development of a new generation of antioxidants and peroxynitrite decomposition catalysts for treatment of diabetic peripheral neuropathy. Published in 2014. This article is a U.S. Government work and is in the public domain in the USA.</description><subject>Animals</subject><subject>antioxidants</subject><subject>Antioxidants - adverse effects</subject><subject>Antioxidants - therapeutic use</subject><subject>Behavior, Animal - drug effects</subject><subject>Catechin - adverse effects</subject><subject>Catechin - analogs & derivatives</subject><subject>Catechin - therapeutic use</subject><subject>Diabetes Mellitus, Type 1 - complications</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetic Neuropathies - metabolism</subject><subject>Diabetic Neuropathies - pathology</subject><subject>Diabetic Neuropathies - physiopathology</subject><subject>Diabetic Neuropathies - prevention & control</subject><subject>diabetic neuropathy</subject><subject>Epidermis - drug effects</subject><subject>Epidermis - innervation</subject><subject>Epidermis - metabolism</subject><subject>Epidermis - pathology</subject><subject>Ferric Compounds - adverse effects</subject><subject>Ferric Compounds - therapeutic use</subject><subject>Ganglia, Spinal - drug effects</subject><subject>Ganglia, Spinal - metabolism</subject><subject>Ganglia, Spinal - pathology</subject><subject>Male</subject><subject>Metalloporphyrins - adverse effects</subject><subject>Metalloporphyrins - therapeutic use</subject><subject>Mice, Inbred C57BL</subject><subject>Motor Neurons - drug effects</subject><subject>Motor Neurons - metabolism</subject><subject>Motor Neurons - pathology</subject><subject>Nerve Tissue Proteins - metabolism</subject><subject>Neural Conduction - drug effects</subject><subject>nitrosative stress</subject><subject>oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Peripheral Nervous System - drug effects</subject><subject>Peripheral Nervous System - metabolism</subject><subject>Peripheral Nervous System - pathology</subject><subject>Peripheral Nervous System - physiopathology</subject><subject>peroxynitrite</subject><subject>Peroxynitrous Acid - antagonists & inhibitors</subject><subject>Peroxynitrous Acid - metabolism</subject><subject>Reaction Time - drug effects</subject><subject>Sensory Receptor Cells - drug effects</subject><subject>Sensory Receptor Cells - metabolism</subject><subject>Sensory Receptor Cells - pathology</subject><subject>superoxide</subject><issn>1520-7552</issn><issn>1520-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kVtv1DAQhSMEohd44A-gSLyUh7Rjx5fNCxIsbUEqF-2CEE-W40y6Llk7tRPo_vs62mUFSDzZ4_nm6HhOlj0jcEoA6FmzDuGUclY9yA4Jp1BILuDh_s7pQXYU4w0AlEywx9kBZWImGZeH2ffPGPzdxtkh2AFz7Zq8D35A6_LpTQ_WuzwVwwrzXg8rf40Oo425b_PG6hoHa_Ieg-1XGHSXOxyDn8DNk-xRq7uIT3fncfb14vzL_F1x9eny_fz1VWE4YVUhKy7LelY2yBlCQw0RsjWsBCNNMgscaCtrUreAIAVPJRVQlmZWgaDIoTzOXm11-7FeY2PQJdud6oNd67BRXlv1d8fZlbr2PxUjUlaCJIGTnUDwtyPGQa1tNNh12qEfoyKiYpUUACyhL_5Bb_wYXPpeoigHSLvmiXq5pUzwMQZs92YIqCkwNQWmpsAS-_xP93vyd0IJONsCv2yHm_8rqbcfFoudZLGdsHHAu_2EDj-UkKXk6tvHS8WX4s1suZyrRXkPW2iwHQ</recordid><startdate>201411</startdate><enddate>201411</enddate><creator>Stavniichuk, Roman</creator><creator>Shevalye, Hanna</creator><creator>Lupachyk, Sergey</creator><creator>Obrosov, Alexander</creator><creator>Groves, John T.</creator><creator>Obrosova, Irina G.</creator><creator>Yorek, Mark A.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>5PM</scope></search><sort><creationdate>201411</creationdate><title>Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy</title><author>Stavniichuk, Roman ; Shevalye, Hanna ; Lupachyk, Sergey ; Obrosov, Alexander ; Groves, John T. ; Obrosova, Irina G. ; Yorek, Mark A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5149-79573b83de54e0d2c167fc430c7c4640502f7b1bf0e076550226033c89062e503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>antioxidants</topic><topic>Antioxidants - adverse effects</topic><topic>Antioxidants - therapeutic use</topic><topic>Behavior, Animal - drug effects</topic><topic>Catechin - adverse effects</topic><topic>Catechin - analogs & derivatives</topic><topic>Catechin - therapeutic use</topic><topic>Diabetes Mellitus, Type 1 - complications</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetic Neuropathies - metabolism</topic><topic>Diabetic Neuropathies - pathology</topic><topic>Diabetic Neuropathies - physiopathology</topic><topic>Diabetic Neuropathies - prevention & control</topic><topic>diabetic neuropathy</topic><topic>Epidermis - drug effects</topic><topic>Epidermis - innervation</topic><topic>Epidermis - metabolism</topic><topic>Epidermis - pathology</topic><topic>Ferric Compounds - adverse effects</topic><topic>Ferric Compounds - therapeutic use</topic><topic>Ganglia, Spinal - drug effects</topic><topic>Ganglia, Spinal - metabolism</topic><topic>Ganglia, Spinal - pathology</topic><topic>Male</topic><topic>Metalloporphyrins - adverse effects</topic><topic>Metalloporphyrins - therapeutic use</topic><topic>Mice, Inbred C57BL</topic><topic>Motor Neurons - drug effects</topic><topic>Motor Neurons - metabolism</topic><topic>Motor Neurons - pathology</topic><topic>Nerve Tissue Proteins - metabolism</topic><topic>Neural Conduction - drug effects</topic><topic>nitrosative stress</topic><topic>oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Peripheral Nervous System - drug effects</topic><topic>Peripheral Nervous System - metabolism</topic><topic>Peripheral Nervous System - pathology</topic><topic>Peripheral Nervous System - physiopathology</topic><topic>peroxynitrite</topic><topic>Peroxynitrous Acid - antagonists & inhibitors</topic><topic>Peroxynitrous Acid - metabolism</topic><topic>Reaction Time - drug effects</topic><topic>Sensory Receptor Cells - drug effects</topic><topic>Sensory Receptor Cells - metabolism</topic><topic>Sensory Receptor Cells - pathology</topic><topic>superoxide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stavniichuk, Roman</creatorcontrib><creatorcontrib>Shevalye, Hanna</creatorcontrib><creatorcontrib>Lupachyk, Sergey</creatorcontrib><creatorcontrib>Obrosov, Alexander</creatorcontrib><creatorcontrib>Groves, John T.</creatorcontrib><creatorcontrib>Obrosova, Irina G.</creatorcontrib><creatorcontrib>Yorek, Mark A.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes/metabolism research and reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stavniichuk, Roman</au><au>Shevalye, Hanna</au><au>Lupachyk, Sergey</au><au>Obrosov, Alexander</au><au>Groves, John T.</au><au>Obrosova, Irina G.</au><au>Yorek, Mark A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy</atitle><jtitle>Diabetes/metabolism research and reviews</jtitle><addtitle>Diabetes Metab Res Rev</addtitle><date>2014-11</date><risdate>2014</risdate><volume>30</volume><issue>8</issue><spage>669</spage><epage>678</epage><pages>669-678</pages><issn>1520-7552</issn><eissn>1520-7560</eissn><coden>DMRRFM</coden><abstract>Background
Peroxynitrite, a product of the reaction of superoxide with nitric oxide, causes oxidative stress with concomitant inactivation of enzymes, poly(ADP‐ribosylation), mitochondrial dysfunction and impaired stress signalling, as well as protein nitration. In this study, we sought to determine the effect of preventing protein nitration or increasing peroxynitrite decomposition on diabetic neuropathy in mice after an extended period of untreated diabetes.
Methods
C57Bl6/J male control and diabetic mice were treated with the peroxynitrite decomposition catalyst Fe(III) tetramesitylporphyrin octasulfonate (FeTMPS, 10 mg/kg/day) or protein nitration inhibitor (−)‐epicatechin gallate (20 mg/kg/day) for 4 weeks, after an initial 28 weeks of hyperglycaemia.
Results
Untreated diabetic mice developed motor and sensory nerve conduction velocity deficits, thermal and mechanical hypoalgesia, tactile allodynia and loss of intraepidermal nerve fibres. Both FeTMPS and epicatechin gallate partially corrected sensory nerve conduction slowing and small sensory nerve fibre dysfunction without alleviation of hyperglycaemia. Correction of motor nerve conduction deficit and increase in intraepidermal nerve fibre density were found with FeTMPS treatment only.
Conclusions
Peroxynitrite injury and protein nitration are implicated in the development of diabetic peripheral neuropathy. The findings indicate that both structural and functional changes of chronic diabetic peripheral neuropathy can be reversed and provide rationale for the development of a new generation of antioxidants and peroxynitrite decomposition catalysts for treatment of diabetic peripheral neuropathy. Published in 2014. This article is a U.S. Government work and is in the public domain in the USA.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>24687457</pmid><doi>10.1002/dmrr.2549</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1520-7552 |
ispartof | Diabetes/metabolism research and reviews, 2014-11, Vol.30 (8), p.669-678 |
issn | 1520-7552 1520-7560 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4177961 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Animals antioxidants Antioxidants - adverse effects Antioxidants - therapeutic use Behavior, Animal - drug effects Catechin - adverse effects Catechin - analogs & derivatives Catechin - therapeutic use Diabetes Mellitus, Type 1 - complications Diabetes Mellitus, Type 1 - drug therapy Diabetic Neuropathies - metabolism Diabetic Neuropathies - pathology Diabetic Neuropathies - physiopathology Diabetic Neuropathies - prevention & control diabetic neuropathy Epidermis - drug effects Epidermis - innervation Epidermis - metabolism Epidermis - pathology Ferric Compounds - adverse effects Ferric Compounds - therapeutic use Ganglia, Spinal - drug effects Ganglia, Spinal - metabolism Ganglia, Spinal - pathology Male Metalloporphyrins - adverse effects Metalloporphyrins - therapeutic use Mice, Inbred C57BL Motor Neurons - drug effects Motor Neurons - metabolism Motor Neurons - pathology Nerve Tissue Proteins - metabolism Neural Conduction - drug effects nitrosative stress oxidative stress Oxidative Stress - drug effects Peripheral Nervous System - drug effects Peripheral Nervous System - metabolism Peripheral Nervous System - pathology Peripheral Nervous System - physiopathology peroxynitrite Peroxynitrous Acid - antagonists & inhibitors Peroxynitrous Acid - metabolism Reaction Time - drug effects Sensory Receptor Cells - drug effects Sensory Receptor Cells - metabolism Sensory Receptor Cells - pathology superoxide |
title | Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T07%3A01%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peroxynitrite%20and%20protein%20nitration%20in%20the%20pathogenesis%20of%20diabetic%20peripheral%20neuropathy&rft.jtitle=Diabetes/metabolism%20research%20and%20reviews&rft.au=Stavniichuk,%20Roman&rft.date=2014-11&rft.volume=30&rft.issue=8&rft.spage=669&rft.epage=678&rft.pages=669-678&rft.issn=1520-7552&rft.eissn=1520-7560&rft.coden=DMRRFM&rft_id=info:doi/10.1002/dmrr.2549&rft_dat=%3Cproquest_pubme%3E3495560001%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1625005525&rft_id=info:pmid/24687457&rfr_iscdi=true |